An Autolus Therapeutics cell therapy has won FDA approval for treating an aggressive blood cancer. It’s the biotech’s first approved product and just the second CAR T-treatment for adults who have ...

Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed ...

Development of B cells, white blood cells that make antibodies, follows a progression of stages: common lymphoid progenitors, pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and then more ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial. The Food and Drug Administration (FDA) ...

Findings published today in Nature Cancer from Charles Mullighan, MBBS (Hons), MSc, MD, deputy director of the St. Jude Comprehensive Cancer Center, Department of Pathology, and collaborators show ...

Please provide your email address to receive an email when new articles are posted on . 40% of responders remained in remission without subsequent stem cell transplantation or other therapy. Ongoing ...

Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...